Lipocine provides progress update on lpcn 1154 phase 3 clinical trial in postpartum depression (ppd)

One-third of patients randomized; topline results expected in 2q 2026 dsmb safety review update planned for 4q 2025 salt lake city , sept. 30, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today provided an update on its ongoing pivotal phase 3 clinical trial evaluating lpcn 1154 (oral brexanolone) for the treatment of postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking